Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). HLS Therapeutics's share price for the quarter that ended in Mar. 2026 was C$4.37. HLS Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 31.27 Mil. Therefore, HLS Therapeutics's market cap for the quarter that ended in Mar. 2026 was C$136.67 Mil.
HLS Therapeutics's quarterly market cap
declined
from Sep. 2025 (C$178.58 Mil) to Dec. 2025 (C$150.74 Mil) and
declined
from Dec. 2025 (C$150.74 Mil) to Mar. 2026 (C$136.67 Mil).
HLS Therapeutics's annual market cap
declined
from Dec. 2023 (C$126.32 Mil) to Dec. 2024 (C$124.95 Mil) but then
increased
from Dec. 2024 (C$124.95 Mil) to Dec. 2025 (C$150.74 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. HLS Therapeutics's Enterprise Value for Today is C$174.36 Mil.
HLS Therapeutics (TSX:HLS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
HLS Therapeutics Market Cap Related Terms
HLS Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
HLS Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a Market Cap of C$129.48 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on HLS Therapeutics and its competitors. According to the industry distribution chart, HLS Therapeutics ranks #615 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 60.1%.
Is HLS Therapeutics' Market Cap too high?
HLS Therapeutics' current Market Cap is C$129.48 Mil. Based on the distribution chart, HLS Therapeutics ranks #615 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #615 out of 1023 companies for Market Cap. This places HLS Therapeutics in the lower half of its industry. The industry median Market Cap is 205.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current Market Cap is C$129.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.14 — trading 7.4% below its estimated fair value. The current Market Cap is C$129.48 Mil. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Market Cap is C$129.48 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.14 is trading 7.4% below its estimated GF Value™ of C$4.47.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Market Cap: C$129.48 Mil
GF Value™: C$4.47 vs. price of C$4.14 (7.4% below fair value)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
